SCHEDULE: Jorey Chernett Discloses 5.1% Stake in Adagene Inc.
Beneficial Ownership Disclosure
Jorey Chernett has reported a 5.1% beneficial ownership stake in Adagene Inc.'s ordinary shares, as detailed in a recent Schedule 13G filing.
Summary
- Jorey Chernett beneficially owns 2,389,060 ordinary shares of Adagene Inc.
- This ownership represents 5.1% of the outstanding ordinary shares of the Issuer.
- The percentage is calculated based on 58,914,087 ordinary shares outstanding as of June 30, 2025, as stated in Adagene Inc.'s Prospectus filed on January 9, 2026.
- The shares were not acquired and are not held for the purpose of changing or influencing the control of Adagene Inc.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a mildly positive signal, as a significant individual investor has taken a passive stake, which can imply confidence in the company's long-term prospects without seeking control.
Positives
- A significant individual investor, Jorey Chernett, has disclosed a 5.1% beneficial ownership stake in Adagene Inc., which can be interpreted as a vote of confidence in the company's long-term prospects.
Negatives
- NA
Risks
- No risks related to Adagene Inc.'s operations or financial health are disclosed in this filing.
Future Outlook
NA
Management Comments
- The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures for passive investors acquiring more than 5% of a company's shares, and this particular filing does not offer specific insights into broader industry trends or competitive dynamics within the biotechnology sector.
Stakeholder Impact
- Shareholders: Disclosure of a new significant passive shareholder (5.1%) provides transparency regarding the ownership structure of Adagene Inc.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of outstanding shares calculation (58,914,087 Ordinary Shares) as per Issuer's Prospectus. |
| 01/09/2026 | Date of Issuer's Prospectus filing with the SEC, which provided the outstanding share count. |
| 03/16/2026 | Date of event requiring the filing of this statement. |
| 03/17/2026 | Close of business date for beneficial ownership calculation by the Reporting Person. |
| 03/18/2026 | Date the Schedule 13G was signed and filed. |
Keywords
Adagene Inc., ADAG, Jorey Chernett, Schedule 13G, beneficial ownership, ordinary shares, biotechnology, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.